Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Symposium on Signalling Pathways in Cancer 2015 – Targeting the MAPK pathway: From RAS to MEK

Signalling Pathways 2015
Start date
13 Mar 2015
End date
14 Mar 2015
Barcelona, Spain

The 2015 Symposium concentrated on targeting the MAPK pathway: from RAS to MEK. The programme covered preclinical data and genetics relevant for the understanding of the functional mechanisms in the RAS/ERK/MEK pathway, regulation of MAPK signalling, the rationale and strategies to inhibiting the pathway, biomarkers, mechanisms of resistance, as well as how to overcome it, and some important interactions with other pathways.

Updates were provided on different aspects important for rational clinical development of novel RAS/ERK/MEK inhibitors, as well as an exploration – from a clinical perspective – of recent achievements and data from ongoing research and clinical trials, targeting the axes of the MAPK pathway across a wide range of solid tumours.


Solange Peters, Switzerland and Giampaolo Tortora, Italy

meeting resources


Webcasts and presentations from Signalling Pathways 2015 are available online for ESMO members and event attendees

Programme 1000x250


View the programme from Signalling Pathways 2015

Contacts 1000x250


Our contact details are here, if you need to get in touch

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.